Summary by Moomoo AI
CRISPR Therapeutics AG, a biotechnology company, was the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission. The amendment, filed on February 5, 2024, indicates that Sumitomo Mitsui Trust Holdings, Inc. (SMTH) and Nikko Asset Management Co., Ltd. (NAM), both based in Japan, have reported shared voting and dispositive power over 3,369,762 common shares of CRISPR Therapeutics, representing 4.24% of the class. The filing was made under Rule 13d-1(b), with both SMTH and NAM classified as parent holding companies and NAM additionally as an investment adviser. The shares are beneficially owned by their subsidiary, Nikko Asset Management Americas, Inc. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.